Disclosure of Interests: Elizabeth Volkmann Grant/research support from: For- bius, Corbus Pharmaceuticals, Consultant of: Boehringer Ingelheim, Forbes, Speakers bureau: Boehringer Ingelheim, Ivan Castelvi Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Acte- lion, Bristol-Myers Squibb, Roche, Sindhu Johnson Grant/research support from: Boehringer Ingelheim, Corbus Pharmaceuticals, GlaxoSmithKline, Roche, Merck, Bayer, Consultant of: Boehringer Ingelheim, Ikaria, Eric Matteson Grant/research support from: Pfizer, Consultant of: Boehringer Ingelheim, Gilead, TymboBo, Arena Pharmaceuticals, Speakers bureau: Simply Speaking, Jörg Distler Grant/research support from: Boehringer Ingelheim, Paid instructor for: Boehringer Ingelheim, Speakers bureau: Boehringer Ingelheim, James Seibold Shareholder of: BriaCell, Pacific Therapeutics, Consultant of: Atlantic, Blade Therapeutics, Eicos Sciences, Eiger Biopharmaceuticals, Indalo Therapeutics, Mitsubishi Tanabe Pharma, Bayer, Xenikos, Boehringer Ingelheim, Camurus, Corbus Pharmaceuticals, EMD Serono, Speakers bureau: Boehringer Ingelheim, Ulrich Costabel Consultant of: Boehringer Ingelheim, Roche, Fibro- gen, Global Blood Therapeutics, Speakers bureau: Boehringer Ingelheim, AstraZeneca, Alexandra James Employee of: Employee of Boehringer Ingelheim, Carl Coeck Employee of: Employee of Boehringer Ingelheim, Manual Quaresma Employee of: Employee of Boehringer Ingelheim, Vincent Cotin Grant/research support from: Boehringer Ingelheim, Roche, Consultant of: Boehringer Ingelheim, Actelion, Bayer, Gilead Sciences, Novartis, Promedior, Celgene, Galapagos, Galacto, He was a member of the INBUILD trial Steering Committee., Speakers bureau: Actelion, Boehringer Ingelheim, Novartis, Roche, Sanofi DOI: 10.1136/annrheumdis-2020-eular.2322

Table 1. Efficacy outcomes at week 52

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ACR20, %</th>
<th>ACR50, %</th>
<th>ACR70, %</th>
<th>mTSS*</th>
<th>mHAQ-DI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nintedanib</td>
<td>75.0***</td>
<td>62.3***</td>
<td>47.8**</td>
<td>0.21</td>
<td>-1.00</td>
</tr>
<tr>
<td>Placebo</td>
<td>73.4</td>
<td>61.4</td>
<td>45.2</td>
<td>0.27</td>
<td>-0.97</td>
</tr>
</tbody>
</table>

*Least-squares mean change from baseline.

**p < 0.05.***p < 0.01; ****p < 0.001 vs MTX alone; not adjusted for multiplicity.

Table: SAT0158

Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: FINCH 3 52-Week Results

Table: SAT0157

Nintedanib Dose Adjustments and Adverse Events in Patients with Progressive Autoimmune Disease-Related Interstitial Lung Diseases in the INBUILD Trial

References:

Disclosure of Interests: Eiji Torikai None declared, Yuji Hirano Speakers bureau: Tanabe-Mitsubishi, Pfizer, Eisai, Abbvie, Bristol-Meyers, Jansen, Astel- las, UCB, Eli-Lilly, Asahikasei, Daichii-Sankyo, Amgen, Daisuke Suzuki: None declared, Yasuhide Kanayama: None declared

DOI: 10.1136/annrheumdis-2020-eular.3019